PMID- 37806993
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231101
IS  - 2523-899X (Electronic)
IS  - 2523-899X (Linking)
VI  - 43
IP  - 5
DP  - 2023 Oct
TI  - Zuo Gui Wan Promotes Osteogenesis via PI3K/AKT Signaling Pathway: Network 
      Pharmacology Analysis and Experimental Validation.
PG  - 1051-1060
LID - 10.1007/s11596-023-2782-x [doi]
AB  - OBJECTIVE: Osteogenesis is vitally important for bone defect repair, and Zuo Gui 
      Wan (ZGW) is a classic prescription in traditional Chinese medicine (TCM) for 
      strengthening bones. However, the specific mechanism by which ZGW regulates 
      osteogenesis is still unclear. The current study is based on a network 
      pharmacology analysis to explore the potential mechanism of ZGW in promoting 
      osteogenesis. METHODS: A network pharmacology analysis followed by experimental 
      validation was applied to explore the potential mechanisms of ZGW in promoting 
      the osteogenesis of bone marrow mesenchymal stem cells (BMSCs). RESULTS: In 
      total, 487 no-repeat targets corresponding to the bioactive components of ZGW 
      were screened, and 175 target genes in the intersection of ZGW and osteogenesis 
      were obtained. And 28 core target genes were then obtained from a PPI network 
      analysis. A GO functional enrichment analysis showed that the relevant biological 
      processes mainly involve the cellular response to chemical stress, metal ions, 
      and lipopolysaccharide. Additionally, KEGG pathway enrichment analysis revealed 
      that multiple signaling pathways, including the 
      phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) signaling pathway, were 
      associated with ZGW-promoted osteogensis. Further experimental validation showed 
      that ZGW could increase alkaline phosphatase (ALP) activity as well as the mRNA 
      and protein levels of ALP, osteocalcin (OCN), and runt related transcription 
      factor 2 (Runx 2). What's more, Western blot analysis results showed that ZGW 
      significantly increased the protein levels of p-PI3K and p-AKT, and the increases 
      of these protein levels significantly receded after the addition of the PI3K 
      inhibitor LY294002. Finally, the upregulated osteogenic-related indicators were 
      also suppressed by the addition of LY294002. CONCLUSION: ZGW promotes the 
      osteogenesis of BMSCs via PI3K/AKT signaling pathway.
CI  - (c) 2023. Huazhong University of Science and Technology.
FAU - Yang, Shuo
AU  - Yang S
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China.
FAU - Wang, Yu-Guo
AU  - Wang YG
AD  - Department of Traditional Chinese Medicine, Chinese PLA General Hospital, 
      Beijing, 100853, China.
FAU - Liu, Zi-Wei
AU  - Liu ZW
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China.
FAU - Qiao, Bo
AU  - Qiao B
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China.
FAU - Xu, Juan
AU  - Xu J
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China. newxj@hotmail.com.
FAU - Zhao, Li-Sheng
AU  - Zhao LS
AD  - Department of Stomatology, The First Medical Center, Chinese PLA General 
      Hospital, Beijing, 100853, China. zhaolisheng@301hospital.com.cn.
LA  - eng
PT  - Journal Article
DEP - 20231009
PL  - China
TA  - Curr Med Sci
JT  - Current medical science
JID - 101729993
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - 0 (zuo gui wan)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
SB  - IM
MH  - *Proto-Oncogene Proteins c-akt/metabolism
MH  - *Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Osteogenesis
MH  - Network Pharmacology
MH  - Cell Differentiation
MH  - Signal Transduction
OTO - NOTNLM
OT  - PI3K/AKT signaling pathway
OT  - Zuo Gui Wan
OT  - bone marrow mesenchymal stem cells
OT  - network pharmacology
OT  - osteogenesis
EDAT- 2023/10/09 00:41
MHDA- 2023/11/01 12:42
CRDT- 2023/10/08 23:06
PHST- 2023/04/24 00:00 [received]
PHST- 2023/07/07 00:00 [accepted]
PHST- 2023/11/01 12:42 [medline]
PHST- 2023/10/09 00:41 [pubmed]
PHST- 2023/10/08 23:06 [entrez]
AID - 10.1007/s11596-023-2782-x [pii]
AID - 10.1007/s11596-023-2782-x [doi]
PST - ppublish
SO  - Curr Med Sci. 2023 Oct;43(5):1051-1060. doi: 10.1007/s11596-023-2782-x. Epub 2023 
      Oct 9.